Core Viewpoint - Enovis Corporation reported its financial results for Q4 and the full year of 2025, highlighting a net sales growth but significant losses due to goodwill impairment charges. Financial Results Summary Fourth Quarter 2025 - Net sales reached $576 million, reflecting a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024 [2] - The Global Reconstructive segment saw a 7% increase in net sales on a reported basis, with 3% organic growth, while the Prevention & Recovery segment experienced a 1% decline on a reported basis and remained flat organically [2] - The company reported a net loss from continuing operations of $519 million, which included a non-cash goodwill impairment charge of $501 million [3][4] - Adjusted EBITDA for the quarter was $112 million [3] Full Year 2025 - Total net sales for the year amounted to $2.2 billion, marking a 7% increase on a reported basis and 6% on an organic basis [5] - The Reconstructive segment grew by 10% on a reported basis and 8% organically, while the Prevention & Recovery segment grew by 4% on both bases [5] - The full year net loss from continuing operations was $1,182 million, which included a non-cash goodwill impairment charge of $1,050 million [6] - Adjusted EBITDA for the full year was reported at $403 million [6] Management Commentary - The CEO of Enovis stated that 2025 was a year of meaningful operational progress, with advancements in integration priorities and above-market organic growth [7] - The company aims to maintain a disciplined focus on commercial execution, innovation, operational efficiency, and financial discipline as it moves into 2026 [8] 2026 Financial Outlook - Enovis expects revenue for 2026 to be in the range of $2.31 to $2.37 billion, reflecting 4-6% organic revenue growth [8] - Adjusted EBITDA is anticipated to be between $425 million and $435 million, with adjusted earnings per share projected to be between $3.52 and $3.73 [8]
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results